Company news

Soligenix, Inc. news in 2022

Soligenix, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

December 22, 2022

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge

December 19, 2022

Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis

December 18, 2022

Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma

December 14, 2022

Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results

November 9, 2022

Soligenix Announces Formation of Psoriasis Medical Advisory Board

October 24, 2022

Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting

October 19, 2022

Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting

September 22, 2022

Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results

August 11, 2022

Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

July 26, 2022

Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients

July 25, 2022

Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen

July 24, 2022

Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis

June 27, 2022

Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine

June 22, 2022

Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform

May 22, 2022

Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results

May 12, 2022

Soligenix Receives $1.4M in Non-Dilutive Government Funding

April 18, 2022

Soligenix Announces Recent Accomplishments And Year-End 2021 Financial Results

March 28, 2022

Soligenix COVID-19 Vaccine, CiVax™, Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron

March 16, 2022

Soligenix Corporate Update Includes NDA Plans for HyBryte(TM)

January 11, 2022

Decks in 2022